Gilead (GILD) Veklury Retains Activity Against Omicron Variant Posted byZacks Equity Research February 14, 2022 Leave a comment on Gilead (GILD) Veklury Retains Activity Against Omicron Variant Gilead’s (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.